Table 1.
Comparison of patient characteristics according to the 17β‐hydroxysteroid dehydrogenase 13 (HSD17B13) rs72613567 genotype
| Patient characteristics | HSD17B13 | HSD17B13 | |||||
|---|---|---|---|---|---|---|---|
|
TA/TA, n = 24 |
T/TA, n = 166 |
T/T, n = 297 |
P value |
T/TA or TA/TA, n = 190 |
T/T, n = 297 |
P value | |
| Age, y | 57 ± 12 | 55 ± 10 | 54 ± 11 | .417 | 55 ± 10 | 54 ± 11 | .313 |
| Sex | |||||||
| Male | 18 (75%) | 121 (73%) | 226 (76%) | .748 | 139 (73%) | 226 (76%) | .466 |
| Female | 6 (25%) | 45 (27%) | 71 (24%) | 51 (27%) | 71 (24%) | ||
| Etiology | |||||||
| ALD/NAFLD | 12 (50%) | 65 (39%) | 125 (42%) | .568 | 77 (41%) | 125 (42%) | .733 |
| Viral | 12 (50%) | 101 (61%) | 172 (58%) | 113 (59%) | 172 (58%) | ||
| Alcohol consumption | |||||||
| Abstinent | 18 (75%) | 117 (70%) | 210 (71%) | .16 | 135 (71%) | 210 (71%) | .052 |
| Moderatea | 6 (25%) | 28 (17%) | 42 (14%) | 34 (18%) | 42 (14%) | ||
| Severeb | 0 (0%) | 3 (2%) | 17 (6%) | 3 (2%) | 17 (6%) | ||
| Unknown | 0 (0%) | 18 (11%) | 28 (9%) | 18 (9%) | 28 (9%) | ||
| Intravenous drug use | 0 (0%) | 2 (1%) | 1 (0%) | .513 | 2 (1%) | 0 (0%) | .566 |
| HCC | 1 (4%) | 4 (2%) | 18 (6%) | .205 | 5 (3%) | 18 (6%) | .082 |
| HVPG, mmHg | 16 ± 6 | 16 ± 6 | 17 ± 7 | .172 | 16 ± 6 | 17 ± 7 | .067 |
| MELD, points | 10 (8‐12) | 9 (7‐11) | 10 (8‐13) | .009 | 9 (8‐12) | 10 (8‐13) | .003 |
| Albumin, g × L−1 | 37 ± 5 | 37 ± 6 | 36 ± 6 | .257 | 37 ± 6 | 36 ± 6 | .077 |
| Bilirubin, mg × dL−1 | 1 (0.8‐1.8) | 1 (0.7‐1.5) | 1.2 (0.8‐2) | .032 | 1 (0.7‐1.6) | 1.2 (0.8‐2) | .011 |
| INR | 1.2 ± 0.2 | 1.2 ± 0.2 | 1.3 ± 0.2 | .002 | 1.2 ± 0.2 | 1.3 ± 0.2 | <.001 |
| Creatinine, mg × dL−1 | 0.8 (0.7‐1) | 0.8 (0.7‐0.9) | 0.8 (0.7‐0.9) | .909 | 0.8 (0.7‐0.9) | 0.8 (0.7‐0.9) | .671 |
| Sodium, mmol × L−1 | 137 ± 3 | 138 ± 4 | 138 ± 4 | .672 | 138 ± 4 | 138 ± 4 | .746 |
Abbreviations: ALD, alcoholic liver disease; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; MELD, model for end‐stage liver disease; NAFLD, non‐alcoholic fatty liver disease.
a
≤30 g/d and ≤20 g/d for males and females respectively.
b
>30 g/d and >20 g/d for males and females respectively.